UBS On-Air: Paul Donovan Daily Audio 'Tariff time?'
At a Glance
Per the full note source, UBS Chief Economist Paul Donovan downplays the near-term market impact of Trump's proposed pharma tariffs, arguing that the delayed 2027–2029 implementation and likely legal challenges reduce the probability-weight markets assign to them. Donovan's main focus is on the expiration of interim 10% tariffs this Friday, which he sees as limited in inflation impact since most pass-through was already absorbed via the unlawful tariff regime. The desk signals that USD direction remains driven more by the affordability crisis and general trade policy noise rather than this specific headline, with no overt currency call.
Key Takeaways
- 01Trump's pharma tariff proposal (100% in Aug 2027, 200% in Aug 2029) is viewed as low probability by UBS due to timeline and legal uncertainty.
- 02Expiring interim tariffs this Friday are the more immediate focus; new replacement tariffs likely limited in inflation pass-through.
- 03No USD-specific trade recommendation; the desk flags the affordability crisis as the dominant macro theme.
- 04Pharma tariffs add risk to USD/CNH and emerging market FX exposed to US imports, but implementation is too distant to trade.
Full Analysis
What the desk is arguing
UBS Chief Economist Paul Donovan dismisses the market significance of President Trump's proposed 100–200% tariffs on imported generic pharmaceuticals, scheduled for August 2027 and 2029. Per the full note source, the desk frames these as low-probability events given the extended timeline and expected legal hurdles, advising investors not to assign a "100% weighting" to their implementation.
Donovan's primary concern is the imminent expiry of interim 10% tariffs this Friday, which the administration plans to replace with approximately 10% tariffs on new products. He argues that since unlawful tariffs were already passed through to consumers, the new levies will only affect prices for previously untariffed goods, limiting the inflation shock.
The counterfactual the desk implicitly rejects is that these pharma tariffs could trigger a broad repricing of USD risk premia or a shift in Fed expectations. Instead, Donovan anchors the debate in the ongoing affordability crisis, suggesting consumer price pressures remain the true macro focus.
Market Implications
Watch USD/CNH and other Asia FX on Friday as markets react to the tariff replacement details. Any surprise expansion of product coverage could trigger a risk-off move, but the default expectation is a muted dollar response given the narrow scope. The delayed pharma tariffs may be a long-tail risk for USD shorts, but no near-term catalyst is identified.
From the original
Inside Washington DC the current focus seems to be trade tariffs, although the affordability crisis continues to be the focus in the wider economy. US President Trump suggested US consumers of imported generic pharmaceuticals would have to pay a 100% tariff from August 2027, and
Related speeches
4 itemsUBS On-Air: Paul Donovan Daily Audio 'They’re back'
The desk interprets recent commentary from UBS regarding the re-emergence of tariffs proposed by US President Trump, which could impact both inflation perceptions and the affordability crisis in the US consumer market. According to Paul Donovan, the implications of these tariffs may be less severe than previous ones given consumer behavior and pricing pressures surrounding high-frequency purchases. Per the full note [source], this suggests that while tariffs are politically charged, their inflationary impact could be mitigated by the context of prior tariffs that became embedded in pricing structures. With significant US consumer spending already under pressure, the market will be keenly watching reactions in inflation metrics and overall consumer sentiment as this situation develops.
UBS On-Air: Paul Donovan Daily Audio 'D-day or Light Brigade?'
More from UBS ON AIR
5 items- UBS ON AIR
UBS On-Air: Paul Donovan Daily Audio 'D-day or Light Brigade?'
- UBS ON AIR
UBS On-Air: Paul Donovan Daily Audio 'Canada, Iran, and US affordability'
- UBS ON AIR
Signal over Noise: Navigating Scylla and Charybdis at Jackson Hole
- UBS ON AIR
Top of the Morning: CIO Equity Pulse - Monthly performance update & outlook